Migraine is among the most common neurologic disorders encountered in clinical practice.1 In the general US population, the annual incidence has been calculated to be approximately 250 per 100 000 with a point prevalence of 10%.2 Females are affected more than males. A variety of prophylactic and abortive medications are being used for treatment and several are being studied in clinical trials. Calcium-channel blockers are frequently used prophylactic medications. We report two patients with migraine successfully treated with amlodipine (Norvasc, Pfizer, Inc), a slow calcium-channel blocker. To our knowledge, these are the first reported cases of amlodipine used in migraine prophylaxis.